Introduction {#S1}
============

The very first report on secretory material from cells was by Wolf in 1967; here he observed the presence of minute phospholipid-rich, pro-coagulant substance from fresh platelet-free plasma which he then termed as "platelet-dusts" ([@B101]). Subsequently, more studies revealed that these "dusts" were actually membranous nanosized particles that contained functional molecules, had downstream effects on recipient cells and could be collected from various bodily fluids ([@B72]; [@B91]). Based on the state of cells and mechanisms of release, these particles can be broadly classified into three main populations: "exosomes"- a pool of vesicles originating from the multivesicular endosome; "microvesicles"- a heterogeneous set of particles which directly shed off the plasma membrane, and "apoptotic bodies"- a much larger group of micelles which bleb off dying cells undergoing apoptosis ([@B24]; [@B65]; [@B70]). Despite such known differences, there still appears to be significant overlaps in both molecular composition and size across all three populations. As it is challenging to purify each individual group, there has been an active shift to use "extracellular vesicles (EVs)" as a collective term to instead describe these secretory vesicles ([@B8]; [@B22]).

EVs as Communicators of Physiology and Disease {#S1.SS1}
----------------------------------------------

Historically, EVs were postulated to be the "garbage trucks" of cells; helping to remove unwanted molecular material out of cells. However, there are an increasing number of studies describing dedicated protein and RNA machineries that regulate the sorting of specific molecular contents (proteins and RNA) into and onto these vesicles ([@B83]; [@B94]; [@B29]; [@B27]; [@B69]; [@B54]; [@B80]). Subsequently, these EVs serve as delivery men by following the unique "addresses" on their surface. Thus, EVs ferry their well-protected molecular cargoes within the bi-lipid boundaries and elicit phenotypic effects on recipient targets, some of which may locate at distal sites from their origin.

The presence and involvement of EVs in biology is best understood in the areas of immunology and cancer. Notably, EVs from dendritic cells can mimic their parental source to aid in antigen presentation and elicit a T cell response in normal physiological processes ([@B70]; [@B108]; [@B88]; [@B93]; [@B76], [@B77]). However, not all EV-mediated communications are beneficial, as in disease settings EVs can aid in the spread of pathogenesis. For example, EVs from primary cancer cells assist in the preparation of the pre-metastasis niche for colonization of migratory cancer cells ([@B30]; [@B66]). Interestingly, one study found that subpopulations of EVs are secreted by a single pool of breast cancer cells and that each EV subtype can influence the formation of micro-metastases in the different organs, depending on the types of surface integrins ([@B26]).

EVs Contribute to Intercellular Brain Communication {#S1.SS2}
---------------------------------------------------

The brain is a complex organ consisting of myriad neural networks between the multitudes of cell types. Hence, it is no surprise that there has been a steadily increasing body of evidence showing how EVs contribute to normal brain function and in central nervous system (CNS)-related diseases ([@B89]). As in other body systems, all cell types of the brain, including neurons, oligodendrocytes, astrocytes and microglial cells, release EVs ([@B19]; [@B38]; [@B4]; [@B95]). Depending on the cell source and the physiological state, the characteristics of secreted EVs can vary accordingly and induce different functions in the brain. For example, EVs from neurons present the AMPA receptor subunit GluR2 and this contributes to synapse maturation and plasticity ([@B40]). Alternatively, EVs from neurons are enriched in syndecans and tetraspanins (e.g., CD81), which are important signaling cues ([@B6]; [@B25]). Hence, EVs can assist in neurite outgrowth and axon path finding. In other instances, EVs can act as important tools for the cross talk between different cell types in the brain, such as when oligodendrocytes release EVs in response to neuronal activity. These EVs carry metabolites such as catalase, which can be delivered back to the neurons for trophic support ([@B20]). Similarly, Schwann cells have been shown to release EVs upon axonal damage ([@B38]), where they could be active at the injury site and aid in axonal regeneration.

Technical Issues in EV Research-Purification Strategies {#S1.SS3}
-------------------------------------------------------

Despite growing knowledge of the importance of EVs to multicellular functions, there is still a lack of consensus on the methodologies for purifying EVs from cells. To date, the most common strategy remains differential ultracentrifugation (UC) due to its accessibility in most laboratories ([@B87]). However, with improved technologies for EV phenotyping, it is becoming increasingly evident that this "gold-standard" UC protocol suffers from several drawbacks; most of which are related to the yield, purity and physical integrity of EVs ([@B13]; [@B58]).

To address this issue, alternative methods for EV purification have been exploited. These include precipitation-based strategies; some of which can be coupled with antibody-capture methods on microfluidic devices or the use of magnetic nanowires ([@B21]; [@B32]; [@B45]; [@B82]). However, these methods may not be scalable, often compromise on EV purity ([@B102]) and require more studies on if the purified EVs can be efficiently eluted and remain complementary to use for any downstream functional characterization. One other method which has gained popularity in recent years is size-exclusion liquid chromatography (LC). Unlike UC, the LC process does not require high speed spins and is scalable for large volume samples when combined with a pre-concentration step. All in all, many supporting reports have verified the feasibility of using LC for EV purification in several serum-free cell culture-based systems and in biological fluids ([@B12]; [@B5]; [@B9]; [@B58]; [@B100]; [@B53]; [@B59]; [@B42]; [@B84]).

Generally in EV research, it is required to use serum-free or exosome-cleared FBS for collection of conditioned media, as regular serum contains numerous microvesicles that can contaminate and confound the downstream analysis of the intended cellular EVs ([@B57]; [@B78]; [@B98]; [@B37]; [@B43]). However, this becomes an issue when considering cell types which will change in serum-depleted media, such as stem cells. In all the previously studies on protocol comparison ([@B74]; [@B2]; [@B85]; [@B73]; [@B105]; [@B48]; [@B81]; [@B84]), none have compared purification of EVs from protein-rich, complex media sources such as stem cell media. Here, we describe a systematic comparison study between UC and LC purified EVs from iPSCs. Interestingly, we find that their molecular contents vary based on protocol, which will have implications on the interpretation of EV content and functionality. Lastly, we cross compared EVs to their parental sources and discuss the feasibility of using these iPSCs for CNS related research.

Materials and Methods {#S2}
=====================

Cell Culture of Pluripotent Stem Cell Lines and Embryonic Fibroblasts {#S2.SS1}
---------------------------------------------------------------------

Mouse embryonic fibroblasts (MEFs, derived from Dr. Paul Fairchild's lab) were grown in complete MEF growth media comprising of DMEM (Life Technologies) supplemented with 15% FBS and 50 μg/ml Penicillin/Streptomycin (P/S). To prepare feeders for stem cell culture, MEFs were treated with mitomycin-C (Sigma, United Kingdom) at 1 mg/ml of MEF media for 2 h. The treated MEFs were then washed three times with PBS and re-plated on fresh culture flasks. Mouse stem cell lines \[embryonic stem cells (ESCs): ESF121, ESF116 and induced pluripotent stem cells (iPSCs): iMEF14, iMEF19\]; all derived from Dr. Paul Fairchild's lab ([@B18]) were first cultured on mitomycin-C treated MEFs feeders. When the cells reached 80% confluence, one-tenth of the cells were plated on fresh feeders while the remainder were plated on 0.1% gelatin-coated plates. For both feeder and feeder-free conditions, cells were cultured in complete mouse stem cell media comprised of DMEM (Lonza, United Kingdom) supplemented with 15% knockout serum-replacement supplement (KOSR) (Life Technologies, United Kingdom), 2 mM [L]{.smallcaps}-glutamine (Life Technologies), 1 mM sodium pyruvate (Life Technologies), 0.1 mM non-essential amino acids (Life Technologies), 50 (μg/ml of P/S, 0.2 mM 2-mercaptoethanol (Sigma) and 106 units of mouse leukaemia inhibitory factor (mLIF, Miltenyi Biotec, United Kingdom). All cells were cultured at 37°C with 5% CO~2~.

Collection of Conditioned Media (CM) for EV Purification {#S2.SS2}
--------------------------------------------------------

For the initial data shown in [Supplementary Figure S1](#FS1){ref-type="supplementary-material"}, pre-spun stem cell (PS) media described here was complete stem cell media that had been pre-spun at 120,000 *g* for 16 h prior to use. The OptiMEM (OM) media was OptiMEM (Life Technologies) supplemented with 50 μg/ml of P/S. For both ESC and iPSC cell lines, the stem cells were cultured twice on 0.1% gelatin-coated plates to get rid of any contaminating feeder cells prior to use for EV collection. For each cell line, 1M cells were initially seeded on a single 10 cm plate. When cells reached 70% confluence (48 or 72 h after plating), the growth media was removed; cells were washed with PBS and replaced with fresh stem cell media, PS or OM depending on the experimental set-up. Conditioned media (CM), ranging from 150--200 ml, was then collected 48 h after media change; cells were harvested by trypsin and counted with a hemocytometer. For each collection, the total CM was first centrifuged at 300 *g*, 5 min to get rid of cellular debris. The supernatant was decanted and further centrifuged at 2,000 *g*, 10 min to get rid of larger particles before subjecting to filtration through a 0.22 μm syringe filter. Subsequently, the CM was split equally into two volumes for UC and LC purification concurrently.

Purification of EVs {#S2.SS3}
-------------------

### Purification of EVs by Differential Centrifugation Protocol (UC) {#S2.SS3.SSS1}

The UC protocol used for purification of EVs is based on an established protocol described by [@B87]. Briefly, the filtered CM was spun at 120,000 *g*, 70 min to pellet EVs. To eliminate any protein contaminations, the pellet was re-suspended in 25 ml of PBS and spun again at 120,000 *g* for 70 min. All centrifugation steps were performed at 4°C. The resultant pellet was then re-suspended in 100 μl of PBS and used fresh for analysis or kept at −80°C for further proteomics analysis.

### Purification of EVs by Size-Exclusion Liquid Chromatography Protocol (LC) {#S2.SS3.SSS2}

The LC protocol used for purification of EVs was based on the method described by [@B86], with some slight modifications. Briefly, the filtered CM was concentrated using the Amicon 100k-Da molecular weight cut-off (MWCO) filters (Millipore, United Kingdom) at 3,500 *g* for 15 min. The concentrate retentate was then loaded onto a Sephacryl S-400 16/60 LC column (GE Healthcare, Sweden) and run with PBS at 0.5 ml/min. Fixed-volume 2 ml fractions of the eluted solutions were then collected with a fraction collector. Based on the 280 nm LC chromatograph, fractions covering the first 280 nm LC peak, designated as "F1," were pooled and concentrated with Amicon 10-kDa MWCO filters (Millipore) at 3,500 *g* for 15 min down to 100 μl of PBS and used fresh for analysis or kept at −80°C for further proteomics analysis. All centrifugation and LC processes were done at 4°C.

Sucrose Gradient Density Centrifugation of EVs {#S2.SS4}
----------------------------------------------

The sucrose gradient density centrifugation protocol used here was based from the protocol described by [@B87]. Briefly, hydroxyethylpiperazine-*N*′-2-ethanesulfonic acid (HEPES)/sucrose stock solution was prepared by mixing 428 g of protease-free sucrose (Sigma) in 500 ml of 20 mM of HEPES buffer. The pH was adjusted to 7.4 with 1M sodium hydroxide (NaOH) and stored at 4°C. Prior to construction of the sucrose gradient, the HEPES/sucrose stock solution was diluted with 20 mM HEPES buffer to generate 10 concentrations of sucrose solutions (0.25--2.5M with 0.25 increments). The EV sample collected after UC and LC was pre-mixed with either 0.25 or 2.5 M of HEPES/sucrose stock to 1 ml total volume and loaded at either at the top or bottom of the linear sucrose gradient respectively. The sucrose gradient was then centrifuged at 200,000 *g* for 16 h or 72 h at 4°C in a SW 40 swing rotor (Beckman Coulter). One ml fractions were carefully collected from the top and each fraction was weighed to obtain an estimated density of each fraction. Each 1ml sucrose fraction was subsequently diluted in 25 ml of PBS and centrifuged at 120,000 *g* for 70 min at 4°C to wash and pellet the particles. The resultant UC pellet of each fraction was re-suspended in 50 μl of PBS and subjected to molecular analysis.

Quantification and Characterization of EVs {#S2.SS5}
------------------------------------------

### Nanoparticle Tracking Analysis (NTA) {#S2.SS5.SSS1}

NTA allows for the quantification of total particle amounts and size distribution of particles based on Brownian motion of particles. All NTA was done with the NTA2.3 software on the NS500 Nanosight machine (Nanosight, Malvern, United Kingdom). Before each run, the NS500 measurements were calibrated with known concentrations of 100 nm silica microspheres to obtain optimum acquisition detector settings and post-acquisition settings. For all our recordings, we used a camera level of 14 (shutter speed 600, camera gain 250) and automatic function for all post-acquisition settings: detection threshold level 5, blur and minimum expected particle size. EV samples were diluted in PBS prior measurement, starting at an initial dilution of 1:100, and then further adjusted for each sample individually to achieve a particle count of between 2 × 10^8^ per ml to 1 × 10^9^ per ml. Once the dilution of the sample was determined, the sample was loaded in the sample chamber and the camera focus was adjusted to make the particles appear as sharp dots of light. Using the *script control* facility on the NTA2.3 software, we recorded five 30 s videos for each sample; incorporating a sample advance and 5 s delay between each recording. The measurements were then analyzed using the *batch process* facility and results were exported as Microsoft Excel spreadsheets for further analysis. If the profiles were not in agreement, measurements were then repeated.

Protein Quantification of EVs and Cell Lysates {#S2.SS6}
----------------------------------------------

Extracellular vesicles and cell lysates were quantified using the microBCA or the BCA assay kit (Thermo Scientific Fisher) respectively as indicated by the manufacturer's instructions.

Western Blotting (WB) {#S2.SS7}
---------------------

Depending on the experimental set-up, either a fixed volume or a set number of particles (as calculated by NTA) from the re-suspension of EV pellet was used. For cells, after trypsin treatment, cells were collected with PBS and spun at 1,500 *g*, 5 min to pellet cells. Cells were washed in PBS and pellet at 1,500 *g*, 5 min again. The supernatant was decanted and the cell pellet was lysed in radioimmunoprecipitation assay (RIPA) buffer for 1 h at 4°C. The mixture was then spun at 16,000 *g*, 20 min. The supernatants were then measured for protein concentration and fixed proteins amounts were used for WB. The EV/cell sample was mixed with 2x Laemilli sample buffer (Bio-Rad, United Kingdom) containing 5% β-mercaptanol and heated at 100°C for 10 min. Samples were then spun-down briefly before being loaded in 1.5 mm, 12% home-made Tris/Glycine SDS-polyacrylamide gels and ran at 170 V for 70 min in running buffer, until the dye front reaches the bottom of the tank. Proteins on the gel were transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore) at 100 V for 70 min in transfer buffer containing 20% methanol. Membranes were then incubated in blocking buffer \[5% fat free milk in Tris Buffer Saline with 0.1% Tween-20 (TBS-T, Sigma)\] for 60 min at room temperature (RT) on a rocker with gentle shaking. After blocking, the membrane was incubated with freshly prepared primary antibody solution \[from Abcam, United Kingdom: anti-Alix, ab117600; anti-Tsg101, ab30871; anti-CD9, ab92726; anti-Calnexin, ab22595; anti-Oct4, ab19857, anti-β-actin, ab8268, all used at 1:1000; from Santa Cruz: anti-CD81(H-121), sc-9158 used at 1:100\] overnight at 4°C or 2 h at RT. Membranes were then washed three times 10 min each using washing buffer (TBS-T) with vigorous shaking before adding the secondary antibody solution \[all from LiCOR, United Kingdom: Goat anti-mouse IgG IRDye^®^ 800CW (925-32210) and 680RD (925-68070); Goat anti-rabbit IgG IRDye^®^ 800CW (925-32211) abd 680RD (925-68071), all used at 1:10000\] and incubated for 2 h at RT. After secondary incubation, membranes were washed three times 10 min each with TBS-T and visualized by scanning both 700- and 800 nm channels on the LI-COR Odyssey CLx infrared imaging system. For re-probing on the same membrane, the membrane was first washed three times 10 min each before re-incubation with the next primary antibody.

Transmission Electron Microscopy (TEM) {#S2.SS8}
--------------------------------------

A 200 mesh nickel carbon/formvar grid (AgarScientific) was placed onto a 10 μl droplet of the EV suspension for 15 min. The grid was then blotted dry with filter paper, immediately transferred to a 15 μl droplet of 2% uranyl acetate for 1 min and protected from light. The grid was again blotted dry with filter paper before being transferred to a 15 μl droplet of filtered distilled and deionized water (ddH~2~0) for 1 min. The grid was then blotted dry and left to air dry on the bench top for 15 min. EVs negatively stained on this grid was then visualized with a JEOL 1010 transmission electron microscope (JEOL, Tokyo, Japan).

Trizol Extraction of RNA From EVs and Cells {#S2.SS9}
-------------------------------------------

Total RNA from EVs and cells were extracted based on the manufacturer's protocol. Briefly, 75 μl of the EV suspension or 2 × 10^5^ cells were mixed in Trizol LS (Life Technologies) and incubated for 5 min at RT. Sixty μl of chloroform was then added and tubes were shaken for 15 s. The mixed samples were then incubated for 15 min at RT before being centrifuged at 12,000 *g* for 15 min at 4°C to derive the three distinct phases. The upper colorless phase was transferred to a new tube and 150 μl of isopropanol with 1 μl of glycogen was added. The sample was vortex briefly and incubated at RT for 10 min. The sample was then centrifuged at 12,000 *g* for 10 min at 4°C and the supernatant were discarded. The remaining white RNA pellet was washed with 300 μl of 75% ethanol and then spun down at 7,500 *g* for 5 min at 4°C. The ethanol was then discarded, and the pellet was air-dried for 5--10 min, till it turned transparent, and then re-dissolved in 20 μl of RNase-free water. The mixture was then incubated at 55--60°C for 15 min on a heat block. RNA concentrations of the samples were then measured using the Quant-iT^TM^ RiboGreen^®^ RNA Assay Kit (Life Technologies).

RNA Profiling With Agilent Bioanalyzer Software {#S2.SS10}
-----------------------------------------------

Quality and size of the EV and cellular RNA were detected using capillary electrophoresis with the Agilent RNA 6000 Pico kit and Agilent RNA small RNA kit on an Agilent 2100 Bioanalyzer^®^ (Agilent Technologies, Santa Clara, CA, United States) according to the manufacturer's protocol.

LC/MS/MS Proteomic Analysis {#S2.SS11}
---------------------------

As both mouse iPSCs and ESCs were derived off the same strain background (CBA/Ca) and derived using the same methodology, we proceeded with proteomics analysis on one of the miPSC line- iMEF14 and one of the mESC line- ESF121. For each cell and EV sample, three biological replicates were prepared and analyzed ([Supplementary Table S1](#TS1){ref-type="supplementary-material"}). All cells and EVs were concentrated by speedvac and lysed with 1% SDS, 25 mM HEPES, 1 mM DTT. Lysates were heated to 95°C for 5 min followed by sonication for 1 min and centrifugation at 14,000 *g* for 15 min. The supernatant was mixed with 1 mM DTT, 8 M urea, 25 mM HEPES, pH 7.6 and transferred to a 10-kDa cut-off centrifugation filtering unit (Pall, Nanosep^®^), and centrifuged at 14,000 *g* for 15 min, followed by an addition of the 8 M urea buffer and centrifugation again. Proteins were alkylated by 50 mM iodoacetamide (IAA) in 8 M urea, 25 mM HEPES for 10 min, The proteins were then centrifuged at 14,000 *g* for 15 min followed by 2 more additions and centrifugations with 8 M urea, 25 mM HEPES. Trypsin (Promega) in 250 mM urea, 50 mM HEPES was added to the cell lysate at a ratio of 1:50 trypsin:protein and incubated overnight at 37°C. The filter units were centrifuged at 14,000 *g* for 15 min followed by another centrifugation with milli-Q water (MQ) and the flow-through was collected. Peptides were cleaned by a strata-X-C-cartridge (Phenomenex).

Before analysis on the Q Exactive (Thermo Fischer Scientific, San Jose, CA, United States), peptides were separated using an Agilent 1200 nano-LC system. Samples were trapped on a Zorbax 300SB-C18, and separated on a NTCC-360/100-5-153 (Nikkyo Technos., Ltd.) column using a gradient of A \[3% acetonitrile (ACN), 0.1% formic acid (FA)\] and B (95% ACN, 0.1% FA), ranging from 7 to 40% B in 240 min with a flow of 0.4 μl/min. The Q Exactive was operated in a data dependent manner, selecting top 5 precursors for fragmentation by HCD. The survey scan was performed at 70,000 resolution from 300--1700 *m/z*, using lock mass at *m/z* 445.120025, with a max injection time of 100 ms and target of 1 × 10^6^ ions. For generation of HCD fragmentation spectra, a max ion injection time of 500 ms and AGC of 1 × 10^5^ were used before fragmentation at 30% normalized collision energy, 17,500 resolution. Precursors were isolated with a width of 2 *m/z* and put on the exclusion list for 70 s. Single and unassigned charge states were rejected from precursor selection.

Proteome discoverer 1.3 with sequest-percolator was used for protein identification. Precursor mass tolerance was set to 10 ppm and for fragments to 0.02 Da. Oxidized methionine and was set as dynamic modification, and carbamidomethylation as static modification. Spectra were matched to a combined *Mus musculus* and *Bos taurus* ensembl 72 database, and results were filtered to 1% FDR. Identifications in *Bos taurus* was considered to originate from FBS and removed. For this set of LC-MS/MS, the reference list used was generated based on all proteins identified within this stem cell set. In this proteomics run, only a short gradient of the cellular and vesicular proteome was subjected to analysis. Hence, the overall proteome of the cell described here may only recapitulate a portion of the total proteome as expected. For classification of commonly identified proteins when comparing two sample types, we calculated the ratio of area of proteins of one sample over the other. Proteins that had a twofold change in ratio were designated to be "up-regulated." These groups were then analyzed in the online platform: Panther to evaluate enrichment of Gene ontology (GO) ([@B50], [@B51]).

Statistics {#S2.SS12}
----------

The Student's *t*-test was used when comparing EVs derived by the UC versus LC purification.

Results {#S3}
=======

Alternative Forms of Serum-Depleted Media Not Feasible for Stem Cells {#S3.SS1}
---------------------------------------------------------------------

In our study, mouse induced pluripotent stem cells (iPSCs) were used as a model for sensitive cells that require complex media types for their cultivation. Unlike differentiated cells, serum is crucial for the maintenance of stem cells in their undifferentiated state. However, in EV research, the use of serum is problematic as serum contains microvesicles, which could be co-purified and interfere with the downstream analysis of EVs. Hence, we used knockout serum replacement (KOSR), which is devoid of serum microvesicles. However, KOSR could still contain other undefined components, which could confound the EV purity.

To evaluate the background particulate counts in KOSR-supplemented (SR) media, we applied the UC purification protocol to unconditioned media and analyzed the pellet. In parallel, two other media types commonly used in EV research were compared; pre-spun SR-media (PS) and serum-free OptiMEM (OM). Interestingly, NTA measurements indicated the presence of nanoparticles in all pellets, most significantly in the SR-media pellet ([Supplementary Figures S1A,B](#FS1){ref-type="supplementary-material"}). Notably, the mode sizes of these nanoparticles appeared to be similar to that of EVs. Next, we assessed the growth and morphology of stem cells in these alternative media types. After a 48 h incubation period, we found that both iPSCs ([Supplementary Figures S1C,D](#FS1){ref-type="supplementary-material"}) and ESCs ([Supplementary Figures S1F,G](#FS1){ref-type="supplementary-material"}) grew differently in these three media types. In PS media, cells appeared less viable based on cell morphology and had much lower total cell counts as compared to regular SR media. In OM media, stem cells proliferated at a higher rate and some colonies displayed altered morphology. As for EVs, the greatest number of particles was recovered from SR CM, followed by OM and lastly PS media ([Supplementary Figures S1E,H](#FS1){ref-type="supplementary-material"}). As we were concerned with the cellular changes caused by the switch in media type, we decided to continue with SR media for subsequent comparisons between UC and LC protocol.

LC Enabled Purification of Stem Cell EVs in a Reproducible Fashion {#S3.SS2}
------------------------------------------------------------------

Since SR media does not contain serum, the detection of vesicles by NTA in the UC pellet of SR media led us to question the nature of these particles. We hypothesized that these "particles" were macromolecular structures of protein aggregates that formed during the high-speed centrifugation.

In LC, there is a lack of high-speed spins. Hence, we fractionated CM from stem cells on the size-exclusion column. Generally, the total protein and particle number profiles overlapped well, such that the fractions with the highest amounts of protein corresponded to the fractions with the highest number of particles ([Figure 1A](#F1){ref-type="fig"}). Overall, we grouped and pooled the fractions into four general fractions: F1--F4. NTA profiles of these four fractions showed that the greatest number of particles to be in F1 followed by F2, while F3 and F4 contained very few particles ([Figure 1B](#F1){ref-type="fig"}). When we compared their particle size distribution graphs, the peak of particle concentration in F1 was significantly higher in cell-derived samples than that of media alone ([Figure 1C](#F1){ref-type="fig"}). Moreover, the presence of EVs exclusively in F1 was confirmed through the detection of common EV markers (Alix and CD9) ([Figure 1D](#F1){ref-type="fig"}). Importantly, this showed that stem cell media contains a fair amount of macromolecular proteins that may appear as particles on NTA. Unlike in LC, these contaminating proteins are inseparable from EVs in the UC process. Furthermore, the LC process was highly reproducible across replicate runs, as seen by the protein chromatographs, western blotting and small RNA profile analysis of replicate collections ([Figures 1E--H](#F1){ref-type="fig"}).

![LC protocol allows for purification of EVs in a reproducible manner. **(A)** Graph showing the protein concentration (μg/μl) and the total number of particles (x10^10^) across the LC run. **(B)** NTA size distribution graphs of the four fractions from mESCs, where F1 is expected to contain the most EVs. **(C)** Graphs comparing the total number of particles (x10^10^) collected through the elution courses of unconditioned media, and CM from miPSCs and mESCs. **(D)** Representative western blots for EV markers (Alix and CD9) in mESC CM. NTA size distribution profiles of the EVs collected from LC-F1 in three replicates (R1--R3) of CM from miPSC **(E)** and mESC **(F)**. **(G)** Representative western blotting pictures for EV markers (Alix and CD9) in duplicate EVs samples (R1--R2) from miPSCs and mESCs. **(H)** Small RNA Bioanalyzer profiles of duplicate EV samples (R1--R2) from miPSCs and mESCs.](fnins-13-01067-g001){#F1}

UC Pelleting Led to Co-precipitation of Non-vesicular Proteins and RNAs With EVs {#S3.SS3}
--------------------------------------------------------------------------------

When comparing UC and LC side-by-side, we detected higher particle yield and total protein and RNA amounts after UC as compared to LC ([Figures 2A--D](#F2){ref-type="fig"}). However, this contradicted our previous study on serum-free culture samples ([@B58]). To understand the reasons underlying the differences, we analyzed the expression levels of common EV markers following both types of collection. Interestingly, when normalized by particle numbers, we detected stronger expression of both Alix and CD9 in LC purified than UC purified samples, whereas OCT-4, a marker of pluripotency, showed the reverse trend ([Figure 2E](#F2){ref-type="fig"}). Next, we compared the expression of the same EV markers in parental cells and EVs based on a fixed protein amount. Unexpectedly, there was no enrichment of EV markers in the UC pellet as compared to cells. To complement our molecular profiling, we next assessed how the biophysical properties of EVs differed by purification protocol. Overall, TEM imaging showed a general cloudy background in the UC samples, which made it difficult to discriminate EVs. In contrast, LC samples had a cleaner background where particles were more easily detected ([Figure 2G](#F2){ref-type="fig"}). Lastly, we calculated the particle per protein ratio (P/μg) and compared them to benchmark values suggested for EV purity ([Table 1](#T1){ref-type="table"}). Here, the P/μg ratio for UC sample was classified as impure, while the LC samples had slightly higher P/μg ratios and were considered of low vesicular purity ([Table 2](#T2){ref-type="table"}).

![Comparison of miPSCs EVs purified by UC or LC. **(A)** NTA size distribution profiles of EVs purified by UC or LC. **(B)** The mode size (nm) and total number of particles (x10^10^) detected by NTA in UC or LC purified samples (*n* = 4, bars represent mean ± SD, ^∗∗^*p* \< 0.01). **(C)** Protein and RNA quantification of EVs in UC and LC purified samples (*n* = 4, bars represent mean ± SD, ^∗^*p* \< 0.05). **(D)** Small RNA Bioanalyzer profiles from UC and LC purified samples **(E)** Representative western blots of UC and LC purified samples. The left panel compares equal numbers of particles (4 × 10^10^), while the right panel compares equal amount of protein from (10 μg) of cell lysate (CL) and EV samples. **(F)** Representative TEM images of EVs purified by UC or LC. The scale bar corresponds to 100 nm.](fnins-13-01067-g002){#F2}

###### 

Table showing the suggested purity index by Webber and Clayton 2013.

  **Purity index**        **P/μg**
  ----------------------- -----------------------
  High vesicular purity   \>3 × 10^10^
  Low vesicular purity    2 × 10^9^--2 × 10^10^
  Unpure vesicles         1.5 × 10^9^

###### 

Table showing the purity ratios of UC and LC samples from both stem cell types.

  **P/μg**    **miPSC**     **mESC**
  ----------- ------------- -------------
  UC pellet   1.6 × 10^9^   4.5 × 10^8^
  LC sample   3.6 × 10^9^   6.2 × 10^9^

One of the methods proposed for deriving pure, clinical-grade EVs is by floating EVs on a discontinuous sucrose gradient overnight ([@B41]), where pure EVs should float at a specific density range of 1.15--1.19 g/ml ([@B87]). Here, we compared EV purity after loading the sucrose gradient either above (bottom-loading) or below the UC pellet (top-loading). Interestingly, we found a discrepancy in the fractions enriched for EV markers and peak particle counts between the two loading types. After bottom-loading, the purified sample unexpectedly peaked in fractions 7--8, which correspond to a density of 1.21--1.22 g/ml ([Figures 3A,B](#F3){ref-type="fig"}). These fractions also contained the greatest amounts of protein ([Figure 3C](#F3){ref-type="fig"}). Hence, we speculated that non-vesicular proteins attached to EVs during the UC process and that this prevented the migration of EVs to their real densities. When further increasing the fractionation time in the sucrose gradient to 72 h, we began to detect more expression of the EV marker CD81 in the expected fractions of pure EVs ([Figures 3D--I](#F3){ref-type="fig"}). Overall, we here show that initial quantification of particle counts and molecular content (proteins and RNAs) in UC pellets were inaccurate. Despite additional prolonged periods of clean-up by either sucrose gradient centrifugation or LC ([Supplementary Figure S2](#FS2){ref-type="supplementary-material"}), we achieved only a marginal improvement in the purity of EVs isolated by UC.

![Sucrose gradient fractionation of UC pellets indicates the co-precipitation of non-vesicular proteins with EVs. **(A)** Graph showing the total number of particles detected in each sucrose gradient fraction after top (light blue) or bottom loading (dark blue) the sample. The fractions are numbered from the top to the bottom of the gradient. **(B)** Representative western blots for EV markers in the top and bottom loaded gradient fractions. UC represents the original UC pellet input material. **(C)** Total protein staining of gradient fractions from the bottom loaded sample. **(D,E)** Graphs showing the total number of particles **(D)** or protein **(E)** detected in each gradient fraction after UC samples were bottom-loaded and centrifuged for 16 h (dark blue bar) or 72 h (striped blue bars). Representative western blots for EV (CD81) and pluripotency (OCT4) markers in UC samples centrifuged on the sucrose gradient for either 16 h **(F)** or 72 h **(G)**. Total protein staining of gradient fractions from UC samples centrifuged on the sucrose gradient for either 16 h **(H)** or 72 h **(I)**.](fnins-13-01067-g003){#F3}

EVs From iPSCs and ESCs Have Similar Size Distribution Profiles and Expression of EV Markers {#S3.SS4}
--------------------------------------------------------------------------------------------

Using the LC method, we next proceeded to purify EVs from two mouse ESCs lines and two iPSCs lines. From the LC chromatograph, it was observed that all four EV fractionation processes generally showed a similar 280 nm absorbance pattern across the eluted volume ([Figures 4A,C](#F4){ref-type="fig"}). As we were only interested in the EVs, we pooled LC fractions across the region where EVs eluted (F1) and analyzed the particles with NTA. As shown in [Figures 4B,D,E](#F4){ref-type="fig"}, the particle size distribution profiles overlapped within each cell type. Moreover, TEM on EVs from both mouse ESCs and iPSCs corroborated the NTA measurements and showed that the particles from both cell types appeared similar. Furthermore, similar levels of EV markers (Alix and CD9) were detected in both mouse iPSC and ESC-derived EVs ([Figures 4F,G](#F4){ref-type="fig"}). Lastly, when analyzing the P/μg ratio of EVs from all four cell lines, we found that all samples were of similar purity ([Figure 4H](#F4){ref-type="fig"}).

![Characterization of EVs from mouse iPSCs and ESCs with NTA, TEM and western blotting. Representative LC chromatographs of two different mouse iPSC cell lines (imef14 and imef19) **(A)** and mouse ESC cell line (ESF121 and ESF116) **(B)**. NTA size distribution profiles of EVs from mouse iPSCs **(C)** and mouse ESCs **(D)**. **(E)** Table showing the mean and mode sizes of EVs from mouse iPSCs and ESCs. **(F)** Representative TEM images of EVs from mouse iPSCs and mouse ESCs. **(G)** Representative western blots of EV markers (Alix and CD9) in replicate samples of EVs from mouse iPSCs and mouse ESCs. **(H)** Table showing the P/μg ratio of EVs purified from mouse iPSCs and ESCs.](fnins-13-01067-g004){#F4}

EVs From ESCs and iPSCs Contain Similar Proteins That Differ Greatly From Their Parental Cells {#S3.SS5}
----------------------------------------------------------------------------------------------

To characterize our EVs more deeply, unbiased LC-MS/MS proteomics analysis were performed on both cell lysates and EVs from our iPSC and ESC lines. As we suspected remnants of contaminating proteins within our EV samples, LC-MS/MS was first performed on unconditioned stem cell media. Overall, 35 cow and 29 mouse proteins were detected ([Table 3](#T3){ref-type="table"}), with the majority of proteins belonging to common protein groups such as albumin, fibronectin, heat shock protein and keratins ([Tables 4](#T4){ref-type="table"}--[6](#T6){ref-type="table"}). Importantly, many of these proteins were also detected in high abundance within our EV samples ([Supplementary Figure S3](#FS3){ref-type="supplementary-material"}). To avoid ambiguity, we removed the entire set of proteins present in media and our EV samples from downstream analysis.

###### 

Table showing the list of cow proteins exclusively identified in the media sample.

  **Species**   **Name of protein**                            **Accession number**
  ------------- ---------------------------------------------- ----------------------
  Bos taurus    Alpha-1-acid glycoprotein                      Q3SZR3
                Alpha-1 -antiproteinase                        P34955
                Alpha-1 B-glycoprotein                         Q2KJF1
                Alpha-2-antiplasmin                            P28800
                Alpha-2-HS-glycoprotein                        P12763
                Alpha-2-macroglobulin                          Q7SIH1
                Antithrombin-lll                               F1MSZ6
                Apolipoprotein A-l                             P15497
                Apolipoprotein A-IV                            F1N3Q7
                C1QC protein (Fragment)                        Q1RMH5
                Complement C3                                  G3×7A5
                Complement component C9                        Q3MHN2
                FGG protein                                    Q3SZZ9
                Fibrinogen alpha chain                         A5PJE3
                Fibrinogen beta chain                          F1MAV0
                Gelsolin                                       F1MJH1
                Haptoglobin                                    G3 × 6K8
                Hemoglobin subunit beta                        P02070
                Inter-alpha-trypsin inhibitor heavy chain H1   F1MMP5
                Inter-alpha-trypsin inhibitor heavy chain H4   F1MMD7
                Leucine-rich alpha-2-glycoprotein 1            Q2KIF2
                Protein AMBP                                   F1MMK9
                Prothrombin                                    P00735
                Serotransferrin                                Q29443
                Serpin A3-5                                    A2I7N1
                Serpin A3-7                                    A2I7N3
                Uncharacterized protein (Fragment)             G3N0V0
                Uncharacterized protein (Fragment)             G5E513
                Uncharacterized protein                        F1N514
                Uncharacterized protein                        F1N076
                Uncharacterized protein                        E1BH06
                Uncharacterized protein                        F1MLW8
                Uncharacterized protein                        F1MCF8
                Vitamin D-binding protein                      F1N5M2

###### 

Table showing the list of mouse proteins exclusively identified in the media sample.

  **Species**    **Class of**                            **Name of**                                           **Accession**
  -------------- --------------------------------------- ----------------------------------------------------- ---------------
  Mus musculus   Fibronectin                             Fibronectin                                           A0A087WS56
                                                         Fibronectin                                           B7ZNJ1
                 Heat shock protein                      Heat shock protein 75 kDa, mitochondrial              Q9CQN1
                                                         Heat shock protein HSP 90-alpha                       P07901
                                                         Heat shock protein HSP 90-beta                        P11499
                 Keratin                                 Keratin, type I cytoskeletal 16                       Q9Z2K1
                                                         Keratin, type I cytoskeletal 17                       Q9QWL7
                                                         Keratin, type I cytoskeletal 18                       P05784
                                                         Keratin, type I cytoskeletal 19                       P19001
                                                         Keratin, type II cytoskeletal 2 epidermal             Q3TTY5
                                                         Keratin, type II cytoskeletal 8                       P11679
                 [L]{.smallcaps}-lactate dehydrogenase   [L]{.smallcaps}-lactate dehydrogenase A chain         P06151
                                                         [L]{.smallcaps}-lactate dehydrogenase B chain         P16125
                 Others                                  Actin, cytoplasmic 1                                  P60710
                                                         Annexin (Fragment)                                    B0V2N7
                                                         Apolipoprotein B-100 (Fragment)                       E9Q1Y3
                                                         Apoptosis facilitator Bcl-2-like protein 14           Q9CPT0
                                                         Beta-actin-like protein 2                             Q8BFZ3
                                                         Complement component C8 beta chain                    Q8BH35
                                                         E3 ubiquitin-protein ligase TRIP12                    A0A087WNZ7
                                                         Filamin-C                                             D3YW87
                                                         Fructose-bisphosphate aldolase A                      P05064
                                                         Gelsolin                                              P13020
                                                         Hemoglobin subunit alpha                              P01942
                                                         Histone H4                                            P62806
                                                         Junction plakoglobin                                  Q02257
                                                         Rho guanine nucleotide exchange factor 9 (Fragment)   S4R1J2
                                                         Ubiquitin-associated domain-containing protein 2      Q8R1K1

###### 

Table showing the list of mouse proteins exclusively identified in the gelatin sample.

  **Species**   **Class of**   **Name of protein**                        **Accession**
  ------------- -------------- ------------------------------------------ ---------------
  Mus           Collagen       Collagen alpha -1 (I) chain                P11087
  musculus                     Collagen alpha-1 (II) chain                P28481
                               Collagen alpha-1 (III) chain               P08121
                               Collagen alpha-1 (V) chain                 088207
                               Collagen alpha-2 (l) chain                 Q01149
                Others         Ig gamma-2A chain C region secreted form   P01864
                               Ig heavy chain V region MOPC 47A           P01786
                               Protein Ahnak                              E9Q616
                               Protein BC067074 (Fragment)                F6Z6Y0

List excludes the detection of 8 uncharacterized sus scrofa proteins.

###### 

Table showing the list of proteins commonly identified in both the media and gelatin sample.

  **Species**    **Class of**   **Name of protein**                **Accession**
  -------------- -------------- ---------------------------------- ---------------
  Bos taurus     Albumin        Serum albumin                      P02769
  Mus musculus   Keratin        Keratin, type II cytoskeletal 79   Q8VED5
                                Keratin, type II cytoskeletal 75   Q8BGZ7
                                Keratin, type II cytoskeletal 5    Q922U2
                                Keratin, type II cytoskeletal 1    P04104
                                Keratin, type I cytoskeletal 10    A2A513

List excludes 2 uncharacterized sus scrofa proteins.

After filtering, a total of 1387 proteins were detected in EVs from either iPSCs or ESCs, where 33.1% of them were present in both groups ([Figure 5A](#F5){ref-type="fig"}). Although there were many more proteins found exclusively in iPSC-EVs than in ESC-EVs (593 vs. 35), GO annotations showed that many of these proteins had similar molecular functions, such as protein binding and cytosolic localization. Next, we considered the 459 proteins which were common to both types of EVs and divided them into three groups: proteins with similar expression, proteins over-represented in iPSC-EVs and proteins over-represented in ESC-EVs. In general, most of these common proteins were found at similar levels in both groups ([Figure 5B](#F5){ref-type="fig"}). As expected, both EVs were enriched in proteins with GO terms such as EV, extracellular exosome, membrane-bound exosome and vesicle ([Figure 5C](#F5){ref-type="fig"}). Moreover, known EV markers like CD9 and CD81 were abundant in both samples and were cross validated by western blotting ([Figure 5D](#F5){ref-type="fig"}). On the other hand, a few GO terms were significantly different between the two groups. For example, GO terms for translation initiation factor activity, translation factor activity, RNA binding and protein hetero oligomerization were over-represented in EVs from iPSCs, while proteins associated with the plasma membrane were over-represented in EVs from ESCs ([Figure 5E](#F5){ref-type="fig"}).

![Proteomics analysis on EVs from mouse iPSCs and ESCs. **(A)** Venn diagram showing the overlap of proteins identified in the two types of stem cell EVs. **(B)** Scatter plot showing the correlation between the areas of commonly identified proteins in both iPSC-EVs and ESC-EVs. All proteins were classified into three distinct groups: up-regulated in iPSC-EVs (red dots), up-regulated in ESC-EVs (blue dots) and of similar levels in both iPSC and ESC-derived EVs (black dots). **(C)** Graph showing the fold enrichments of iPSC-EVs and ESC-EVs over the reference list, in four vesicle-related GO terms: extracellular vesicle, extracellular exosome, membrane-bound exosome and vesicle. **(D)** List of individual proteins identified in these same four GO terms. **(E)** A subset of significantly enriched GO terms for proteins up regulated in iPSC or ESC-derived EVs. Proteins are grouped under four categories: all EV IDs (black bar), proteins at similar levels in both iPSC-EVs and ESC-EVs (gray bar), up-regulated in iPSC-EVs (red bar) and up-regulated in ESC-EVs (blue bar).](fnins-13-01067-g005){#F5}

To analyze if the similarities in the EVs was related to their parental cells, we next compared the cellular proteomes of matched iPSCs and ESCs to their respective EVs. As expected, more proteins were detected in cells than in EVs (3565 versus 1387). Of the proteins identified, 71.6% overlapped in both cell types ([Figure 6A](#F6){ref-type="fig"}). As for proteins exclusive to each cell type, most of them mapped to the same GO terms (e.g., nucleotide and RNA binding, organelle and membrane). Similar to before, common proteins were separated into three groups; those expressed similarly in both, those over-represented in iPSCs and those over-represented in ESCs. Although there were variations in GO term enrichments between the two cell types, none of these differences were found to be significant. Interestingly, the scatter plot of individual proteins showed the exception of two outliers: mitochondrial ribosomal protein S25 (MRPS25) and activating signal co-integrator 1 complex subunit 3 (ASCC3), both of which were more abundant in ESCs than in iPSCs ([Figure 6B](#F6){ref-type="fig"}).

![Preliminary proteomics comparing GO terms of proteins from mouse iPSC and ESC EVs and cells. Venn diagram showing the overlap of proteins identified in the two types of stem cells **(A)**, in mouse iPSC-EVs and iPSCs **(B)** and in mouse ESC-EVs and ESCs **(C)**. Scatter plots showing the correlation between the areas of commonly identified proteins in each of these three pairing: iPSCs versus ESCs **(D)**, iPSC-EVs versus iPSCs **(E)** and ESC-EVs versus ESCs **(F)**. All proteins were classified into three distinct groups as indicated in the graphs. A subset of significantly enriched GO terms for proteins considered to be up regulated in either iPSCs or ESCs **(G)**, iPSC-EVs or iPSCs **(H)**, and ESC-EVs or ESCs **(I)**.](fnins-13-01067-g006){#F6}

Next, we compared each EV sample back to their parent cells. Interestingly, the overlap of cellular proteins in their corresponding EVs was quite low; 28.5% for iPSCs and 15.5% for ESCs ([Figures 6C,E](#F6){ref-type="fig"}). This was further supported by the scatter plots showing correlation expression of all identified proteins in EVs versus cells ([Figures 6D,F](#F6){ref-type="fig"}). To understand the nature of these differences, we applied GO analysis to the different groups of proteins. In the iPSC set, GO terms for translation initiation factor activity, translation factor activity, RNA binding, extracellular matrix and extracellular space were all found to be over-represented in EVs. In contrast, proteins with GO terms for structural constituent of ribosome, mRNA binding, cytosolic part and intracellular non-membrane-bounded organelle were over-represented in cells ([Figure 6G](#F6){ref-type="fig"}). As proteins detected in ESC-EVs, we observed an enrichment in GO terms for glycolipid binding, G-protein beta/gamma-subunit complex binding, external side of plasma membrane and extracellular matrix component in the EVs. In contrast, ESC proteins were over-represented in proteins with GO terms for the structural constituent of cytoskeleton, histone binding, protein-DNA complex assembly and chromatin assembly or disassembly, as compared to EVs ([Figure 6H](#F6){ref-type="fig"}). Interestingly, there were some GO terms which were similarly enriched in EVs and cells across both stem cell types. For example, the GO term basal lamina was enriched in EVs from both iPSCs and ESCs when compared to their parent cells. On the other hand, GO terms for protein-DNA complex subunit organization, DNA replication-dependent nucleosome organization, nuclear chromosome and nuclear nucleosome were enriched in both cell samples as compared to their EVs ([Figure 6I](#F6){ref-type="fig"}).

Discussion {#S4}
==========

In this study, we cross compared the isolation of EVs from complex, protein rich media using two methods: the gold-standard of UC versus an LC method. Due to the presence of microvesicles in serum, many researchers have turned to alternative media types like pre-spun media or entirely serum-free solutions reconstituted with recombinant protein substitutes for serum component ([@B44]). Unfortunately, there have been doubts about the clearance efficiency of microvesicles from pre-spun media ([@B37]), and it is not feasible to reconstitute serum components for certain sensitive cell types. Here, we have demonstrated the phenotypic changes that occur in stem cells after short term incubation in these different media types. Although serum-free alternatives for cell types such as neurons and astrocytes have been developed ([@B11]; [@B68]), these remain poorly defined, protein rich alternatives that may induce unwanted molecular changes and lead to growth of selective populations ([@B7]). Despite the growing number of studies comparing EV isolation methods, there is still only limited knowledge about the molecular profiles of EVs collected from protein rich media types and their implications on molecular contents of EVs.

In our findings, we highlight various problems associated with the UC protocol. First, we identify an issue with high particle counts in UC pellets from unconditioned media, despite the lack of serum in KOSR. However, when we fractionated the unconditioned media with LC, most particles were found in later fractions corresponding with high protein amounts. Hence, this led us to speculate that the high-speed spins in UC promote the precipitation of protein aggregates, which then appear as nano-sized particles on NTA.

In our side-by-side comparison of UC and LC, the UC pellet contained more particles, protein and RNA than the LC sample. This result was rather unexpected, as the opposite trend was previously reported in serum-free CM ([@B58]). As we are aware that protein aggregates in the UC pellet can appear as particles on the NTA, we remain unsure of the reliability of our NTA and protein quantifications. Thus, we used multitude of other technologies for our subsequent detailed comparison and characterization studies.

First, we checked the expression levels of well-established EV and stem cell markers when loading equal numbers of particles. Surprisingly, the expression level of OCT-4 was inversely correlated to that of the EV markers. Although OCT-4 is reported to be present in ESC-EVs ([@B71]), more recent work has shown that OCT-4 can also be secreted from cells directly into the extracellular environment ([@B96]). Hence, we speculate that some portion of this secreted OCT-4 protein in the CM might pellet together with stem cell EVs during the UC process. This hypothesis would explain the high particle counts and levels of OCT-4 detected by western blotting in UC-purified EVs. Apart from proteins, we also observed significant differences in other EV properties after isolation with UC and LC, such as their small RNA profiles and TEM images of vesicles. In the latter, we hypothesized that the presence of free protein in the UC pellet would contribute to the cloudy background that interfered with our visualization of the EVs. Furthermore, the P/μg ratio was lower after UC than LC purification; which corroborated our data suggesting that the UC pellet displayed lower vesicle purity. However, here we realize that interpretation of the vesicle purity ratio (P/μg) may need to be re-considered for protein rich substances. Since some protein aggregates may be mistakenly counted as EVs when using NTA, purified samples with more protein aggregates would appear to have a higher purity ratio than they do.

Next, we subjected the UC pellet to additional clean-up strategies to test for the presence of contaminating proteins. The first clean up strategy we attempted was sucrose gradient centrifugation. Previously, it has been reported that EVs float at 1.15--1.19 g/ml, which is slightly different to vesicles originating from cellular organelles such as the endoplasmic reticulum (1.18--1.25 g/ml) or the Golgi (1.05--1.12 g/ml) ([@B87]). These floatation intervals have been verified on EVs from different cellular sources and found to be reproducible regardless of the method of loading the EV sample on the top or bottom of the sucrose gradient. However, others have debated that overnight centrifugation was insufficient for vesicles to efficiently penetrate in the denser fractions and reach density equilibrium within 16 h centrifugation period ([@B104]; [@B28]). Hence, we here tested both loading strategies (top versus bottom) and at two different lengths of centrifugation timings (16 h versus 72 h). Unexpectedly, there was great inconsistency in the fractions showing the highest total particle counts and expression of EV markers between the two loading strategies. In the bottom-loaded sample, the gradient fractions positive for EV markers overlapped with those containing non-vesicular protein bands. Hence, we hypothesize that the EVs in the UC pellet may be associated with protein aggregates and thus float at these higher densities instead of their actual density.

Interestingly, with the longer overnight centrifugation, the expression of CD81 became more diverse. We hypothesized that after this longer incubation period, a portion of EVs were able to escape from the protein aggregates and float at their expected densities. In hindsight though, CD81 expression still appeared relatively higher in the higher density fractions. Despite this data, it is very difficult to conclude whether the particles appearing at higher densities and stained positively for CD81 are EVs bound to non-vesicular proteins or they could be true EVs that float at a higher density. However, there is the possibility that some of these EV-protein associations are transient, whilst others may be more permanent due the high gravitational forces inherent in the UC procedure. Another strategy we tried was to fractionate the UC pellet on an LC column. Interestingly, this revealed an additional protein peak immediately after the initial EV peak, though the particles in this second peak did not express any of the EV markers we tested. This result further supports our previous deduction that proteins can appear as particles on the NTA. From these results, we conclude that UC purification of EVs may require additional clean-up to increase the purity of EVs, despite that these steps would compromise the final EV yield as seen by another recent study ([@B62]).

When applying LC to stem cell CM, the fractionation pattern was reproducible across replicates and consistent across the two stem cell types. However, we noticed that there was a lack of distinct cut-off points between the particle and protein peaks in the LC profile of stem cell CM. This led us to speculate that, due to the high protein content in the media, the resolution of fractionation may require more improvements; this can be in the form of sequential LC steps or with an alternative taller column. We briefly tested the sequential LC approach here and noticed that in the second LC run there was slightly lower expression of the transmembrane protein CD9, while the opposite was true for the intraluminal protein (Tsg101) ([Supplementary Figure S4](#FS4){ref-type="supplementary-material"}). Interestingly, this suggests that more caution is required when checking the expression of established EV markers identification. In this scenario, the lower expression of CD9 in the second LC may indicate that some CD9 initially detected might be contributed by non-EV proteins.

Despite our efforts to clean-up the EV product, there remains the presence of huge protein bands as seen by Ponceau S staining. From literature, KOSR contains high amounts of albumin and other proteins to replace the serum component. We postulated that the pre-concentration step with spin filters might have caused the capture of these protein aggregates in the filters. To bypass this, one could consider the use of tangential flow filtration (TFF) devices, which function through diafiltration-based processes. On the other hand, some contaminating proteins on EVs may be due to the presence of cell adhesion molecules like connexins, integrins and cadherins ([@B1]; [@B75]; [@B79]) which would make EVs particularly adhesive to free proteins in the circulation.

Unlike previous studies on stem cell derived-EVs, which were collected from serum-free conditions ([@B71]; [@B103]; [@B33]), we used serum-replacement media to avoid the differentiation of our stem cells in the absence of serum. To identify the background of proteins in the unconditioned media, we applied the use of a mass spectrometry method. We found a relatively high amount of cow albumin and keratin proteins. As the serum-replacement media contained AlbuMax^TM^ (Life Technologies, United Kingdom), we believed that this was the main source of cow albumin in our samples and pre-filtered these proteins out of downstream analysis.

Generally, the EVs from iPSCs and ESCs have relatively similar proteomes. Although there was a disparity in the total number of proteins detected in the iPSC-EVs and ESC-EVs, most of the specifically expressed proteins did not show a significant difference in GO terms enrichments and may not impact on cell functionality. Furthermore, our proteomics data highlighted the identities of other EV markers, which could serve as useful indicators for future studies on stem cell EVs.

Next, to trace if the similarities between EVs was related to their parental cells, we analyzed the proteomes of the cells from which the EVs were derived from. Although the proteomes of both stem cell types were highly similar, there was much less overlap between EVs and their corresponding parental source. This was largely due to the lower overall number of detected proteins in EVs than in cells. This is not at all unexpected, as it can be attributed to the size differences between a vesicle (100 nm) and a cell (\>5 μm). However, the enrichment of specific GO terms in EVs over cells illustrates the differences between their biological contents and may be linked to their downstream functionality. In hindsight though, we cannot be certain how the background from the basal media may have also affected the LC-MS run and the downstream protein readout.

There is an overwhelming amount of research commenting on the similarities and differences between ESCs and iPSCs ([@B10]; [@B56]; [@B67]), and the variation between ESC and iPSC clones due to the type of donor cells ([@B97]; [@B63]; [@B56]), their methylation status and transcriptomes ([@B35]; [@B46]; [@B61]).

On the other hand, There have only been a handful of published proteomics studies on mouse ([@B23]) and human iPSCs and ESCs ([@B67]; [@B55]), all of which have been performed on different ESC and iPSC lines. There have also been some recent studies on EVs from iPSCs and iPSC-derivatives ([@B106]; [@B47]; [@B107]; [@B15]; [@B16]; [@B39]; [@B60]), though there is yet to be any proteomic data on EVs from pluripotent cell sources. Hence, due to the variation between lines, the biological data here might not be applicable to all other pluripotent stem cells.

In neurological diseases, standard methods of monitoring such as CT or MRI scans are costly, less sensitive and requires expertise interpretation. The use of traditional tissue biopsy or blood liquid biopsy in CNS-related disease has been elusive due to the presence of the blood brain barrier functions ([@B14]). Recently though, some have capitalized on EVs in the cerebrospinal fluid (CSF) to monitor the brain and CNS ([@B99]; [@B90]; [@B52]; [@B64]). However, the lumbar tap procedure for CSF extraction is painful and often only very small volumes of CSF can be extracted. Hence, we envision here that our study will assist other EV researchers on the methodology for EV purification from these precious sources.

Besides biology, EVs can also be exploited by loading therapeutic cargoes; both naturally and after engineering. In the former, there are many excellent reviews on how EVs from mesenchymal stem cells (MSCs) can alleviate disease through EV therapy in CNS-related diseases ([@B34]; [@B36]; [@B49]). On the other hand, others have cleverly designed targeting moieties on the surface of EVs and encapsulated genetic cargoes or drugs for therapeutic purposes ([@B3]; [@B17]; [@B31]; [@B92]). Here, we describe EVs from iPSCs that may serve as an alternative resource. Furthermore, we performed unbiased protein characterization of these EVs with the hope that this can assist in the future design and molecular engineering of EVs for specific personalized therapy.

Conclusion {#S5}
==========

Here, we describe a study investigating the isolation of EVs from protein-rich complex media types, using stem cells as a model. Initially, our step-by-step comparison between UC and LC contradicted our expectations. Using additional technologies, we illustrate the possible causes and sources of protein contamination in the UC pellet and how they can be reduced with additional clean-up steps. However, these processes are somewhat inefficient and compromise on the final output. On the other hand, although LC was a better alternative to UC, the resultant EV population still appears to be of low purity. The purity of EVs is of great importance in all forms of EV research, from deducing biological functions to use as therapeutic agents, as contaminations may confound interpretations. Furthermore, we highlight the need to be cautious when using current tools for the interpretation of EVs purified from complex media or biological fluids. Lastly, we analyzed the protein content of these EVs and briefly discuss their potential in future CNS-related research.
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###### 

Alternative types of serum-depleted media for EV collection from stem cells. **(A)** NTA size distribution profiles of UC pellets after centrifugation of the three types of media: KOSR-supplemented stem cell media (SR), Pre-spun stem cell media (PS) and serum-free media/OptiMEM (OM). **(B)** Table showing the mode size (nm) and concentration of particles (x10^9^/ml) detected in the UC pellet of each media type. Representative bright-field images of mouse iPSCs **(C)** and mouse ESCs **(F)** after 48 h culture in SR, PS, or OM. Graphs comparing the total number of viable cells in the miPSCs **(D)** and mESCs **(E)** cultures at CM collection. Graphs comparing the total concentration of particles (x10^10^/ml) detected by NTA in the UC pellet of miPSCs **(G)** and mESCs **(H)** in the three different media types.

###### 

Click here for additional data file.

###### 

LC fractionation of UC pellets reveals co-precipitation of non-vesicular proteins with EVs in the UC pellet. **(A)** Schematic outline of the LC fractionation protocol of UC pellets. **(B)** LC chromatograph showing the 280 nm absorbance of the elution course from the LC column for three replicate samples (R1--R3). The first fraction (pink box) corresponds to the region where EVs elute. The second fraction (orange box) shows the appearance of another peak after the EVs. **(C)** NTA size distribution profiles of particles in the original UC sample (blue), and in the first (box 1; UC-LC1) and second (box 2; UC-LC2) LC fractions. **(D)** Graph on the left shows the mode size (nm) of particles in the original UC pellet, UC-LC1 and UC-LC2 (*n* = 3, bar represents mean ± SD). Graph on the right shows the percentage of particles detected in the UC pellet versus UC-LC1 (*n* = 3, bar represents mean ± SD). **(E)** Representative western blots for EV (Alix and CD9) and pluripotency (OCT4) markers when loading the same amount of particles from the UC pellet and UC-LC1 fraction. **(F)** Total protein staining of the UC pellet, UC-LC1 and UC-LC2. **(G)** Representative TEM images of the UC pellet and UC-LC1. Here the UC-LC1 sample appears to have a decreased background as compared to UC. The scale bar corresponds to 100 nm.

###### 

Click here for additional data file.

###### 

Detection of non-mouse proteins in mouse derived EVs. Scatter plot showing the areas of proteins identified in the preliminary analysis of iPSC- and ESC-EV samples. Proteins from mouse (black dots), cow (red dots) and pig (blue dots) are indicated.

###### 

Click here for additional data file.

###### 

Sequential LC fraction improves EV purity marginally. **(A)** Schematic outline of the sequential LC fractionation set-up. **(B)** LC chromatograph showing the 280 nm absorbance of the elution course from the LC column for three replicate samples (R1--R3). The first fraction (green box) corresponds to the region where EVs elute. **(C)** NTA size distribution profiles of particles in the first LC sample versus the second LC run (LC′1). **(D)** On the left, the mode size of particles in the original LC sample and the LC′1 sample appears to be similar (*n* = 3). On the right, graph showing overall percentage of particles recovered as compared to the input material. **(E)** Representative western blotting pictures when loading the same amount of particles for LC and LC'1. **(F)** Total protein staining of the membrane with LC and LC'1 samples.
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Click here for additional data file.

###### 

Table showing the protein expression of replicate runs of cells and EVs purified from mouse ESC and mouse iPSC.
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Click here for additional data file.
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